Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ameluz and BBL HEROic for Actinic Keratoses and Photodamage
NCT07053852Phase 1Completed
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 5-aminolevulinic acid in actinic keratosis (AK) and photodamage. Primary endpoints: Percentage of clearance of actinic keratoses at 2 months and Cosmetic outcomes at 2 months. Started Jun 2025; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)photodamage
Beyond the preview
Go deeper on NCT07053852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053852.